Literature DB >> 1581210

Lymphoid subsets and prognostic factors in multiple myeloma. Cooperative Group for the Study of Monoclonal Gammopathies.

J F San Miguel1, M González, A Gascón, M J Moro, J M Hernández, F Ortega, R Jiménez, L Guerras, M Romero, F Casanova.   

Abstract

In a uniform series of 170 untreated myeloma patients (MM) we investigated the distribution of T cell subsets in peripheral blood (PB) and their relationship with the most relevant disease characteristics, including survival. CD4 cells were significantly decreased both in percentage and absolute numbers (P less than 0.0001). On the other hand, the CD8 cells only showed a slight increase in relative numbers. Upon correlating the abnormalities in the distribution of T cells with other clinical and biological disease characteristics the most remarkable correlation was with survival. A low number of CD4 cells (less than 700 x 10(6)/l) was associated with both an advanced clinical stage and a shorter survival (20 v. 43 months, P = 0.01). Moreover, a significant correlation also exists between the decrease in CD4 cells and both high beta 2-microglobulin (beta 2M) levels and anaemia. On the other hand, no relationship was found with the type of M-component nor with the plasma cell phenotype. Finally multivariate analysis showed that the number of CD4 cells add independent prognostic information to other well-established tests for the assessment of disease outcome in patients with multiple myeloma.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1581210     DOI: 10.1111/j.1365-2141.1992.tb08137.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  15 in total

1.  Therapeutic effects of CSF1R-blocking antibodies in multiple myeloma.

Authors:  Q Wang; Y Lu; R Li; Y Jiang; Y Zheng; J Qian; E Bi; C Zheng; J Hou; S Wang; Q Yi
Journal:  Leukemia       Date:  2017-06-19       Impact factor: 11.528

Review 2.  Lymphocyte subsets as prognostic markers for cancer patients receiving immunomodulative therapy.

Authors:  M Hernberg
Journal:  Med Oncol       Date:  1999-09       Impact factor: 3.064

Review 3.  BMT CTN Myeloma Intergroup Workshop on Minimal Residual Disease and Immune Profiling: Summary and Recommendations from the Organizing Committee.

Authors:  Sarah A Holstein; Hervé Avet-Loiseau; Theresa Hahn; Christine M Ho; Jens G Lohr; Nikhil C Munshi; Bruno Paiva; Marcelo C Pasquini; Joseph D Tario; Saad Z Usmani; Paul K Wallace; Katja Weisel; Philip L McCarthy
Journal:  Biol Blood Marrow Transplant       Date:  2017-12-11       Impact factor: 5.742

4.  Exhausted and outnumbered: CD4+ T cells in the myeloma battlefield.

Authors:  Elisabet E Manasanch; Morie A Gertz
Journal:  Leuk Lymphoma       Date:  2020-06-16

5.  Circulating Ki67 positive lymphocytes in multiple myeloma and benign monoclonal gammopathy.

Authors:  A Miguel-Garcia; E Matutes; F Tarin; J Garcia-Talavera; A Miguel-Sosa; F Carbonell; D Catovsky
Journal:  J Clin Pathol       Date:  1995-09       Impact factor: 3.411

6.  Immune signatures associated with improved progression-free and overall survival for myeloma patients treated with AHSCT.

Authors:  Christine M Ho; Philip L McCarthy; Paul K Wallace; Yali Zhang; Ahmad Fora; Patrick Mellors; Joseph D Tario; Benjamin L S McCarthy; George L Chen; Sarah A Holstein; Sophia R Balderman; Xuefang Cao; Bruno Paiva; Theresa Hahn
Journal:  Blood Adv       Date:  2017-06-20

Review 7.  The cellular immune system in myelomagenesis: NK cells and T cells in the development of myeloma [corrected] and their uses in immunotherapies.

Authors:  T Dosani; M Carlsten; I Maric; O Landgren
Journal:  Blood Cancer J       Date:  2015-04-17       Impact factor: 11.037

Review 8.  Myeloid-derived suppressor cells as therapeutic target in hematological malignancies.

Authors:  Kim De Veirman; Els Van Valckenborgh; Qods Lahmar; Xenia Geeraerts; Elke De Bruyne; Eline Menu; Ivan Van Riet; Karin Vanderkerken; Jo A Van Ginderachter
Journal:  Front Oncol       Date:  2014-12-08       Impact factor: 6.244

9.  Lymphocyte recovery and clinical response in multiple myeloma patients receiving interferon alpha 2 beta after intensive therapy.

Authors:  B C Millar; J B Bell; R L Powles
Journal:  Br J Cancer       Date:  1996-01       Impact factor: 7.640

10.  Impact of lenalidomide maintenance on the immune environment of multiple myeloma patients with low tumor burden after autologous stem cell transplantation.

Authors:  Karel Fostier; Jo Caers; Nathalie Meuleman; Katrijn Broos; Jurgen Corthals; Kris Thielemans; Rik Schots; Brenda De Keersmaecker
Journal:  Oncotarget       Date:  2018-04-17
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.